Slide 1: Company Overview
DRIVES EVERYTHING WE DO © 2013 CorMedix Company Overview NYSE MKT: CRMD December 2013
Slide 2: Forward Looking Statements
2 © 2013 CorMedix Forward Looking Statements This presentation contains certain statements that constitute forward-looking statements within the meaning of the federal securities laws. Statements that are not historical facts, including statements about our beliefs and expectations, are forward-look
Slide 3: Investment Highlights
© 2013 CorMedix Investment Highlights CorMedix ( NYSE MKT: CRMD ) develops and markets products to treat renal, cardiac and infectious diseases Lead product Neutrolin ® Class III CE Mark approved (drug-device) in July 2013 Catheter-related bloodstream infections (CRBSI) cost approx. $25,000-40,000/h
Slide 4: Catheter Safety and Efficacy: By the Numbers
4 Catheter Safety and Efficacy: By the Numbers © 2013 CorMedix 15 Million 80,000 $25,000- 40,000 $6+ Billion Total CRBSI cost to the U.S. healthcare system per year 250,000 Estimated CRBSI across all hospitals Sources: U.S. Centers for Disease Control and Prevention. Trish Perl, M.D., professor, med
Slide 5: What could save the US Healthcare system Billions per year?
What could save the US Healthcare system Billions per year? © 2013 CorMedix
Slide 6: Neutrolin
6 © 2013 CorMedix Neutrolin ® A Catheter Lock Solution (CLS) that fills the catheter to: • Significantly decrease CRBSI • Decrease catheter blood clotting episodes Neutrolin ® contains: • Taurolidine , an anti-infective • Citrate , a buffering compound • Heparin , an anticoagulant
Slide 7: Neutrolin: Mechanism of Action
7 © 2013 CorMedix Neutrolin ® Mechanism of Action Taurolidine: a taurine amino acid derivative • Shows broad antibacterial action against gram-positive and gram- negative bacteria, mycobacteria and some clinically relevant fungi • Shows a higher affinity than mannose (the natural substrate) for bact
Slide 8: Why is Antimicrobial Resistance a Problem?
8 © 2013 CorMedix Why is Antimicrobial Resistance a Problem? • Antibiotic/antimicrobial resistant infections cause: – prolonged illness – greater risk of death – higher treatment costs • A high percentage of hospital-acquired infections are caused by highly resistant microorganisms – Dialysis patien
Slide 9: Taurolidine-Based Catheter Lock Solution: Demonstrated Effectiveness
9 © 2013 CorMedix Taurolidine-Based Catheter Lock Solution: Demonstrated Effectiveness *From 58 patients 1. Allon M Clin Infect Dis (2003) 36 (12):1539-44, 2. Betjes Nephrol Dial Transplant (2004) 19:1546-1551, 3. Sodemann K et al Poster: ASN 2001, 4. Bisseling, T. M., M. C. Willems, et al. (2010) C
Slide 10: Neutrolin Growth Strategy
Successful EU Launch for Hemodialysis Label Expansion in EU Rollout to Other Key Countries Neutrolin Growth Strategy © 2013 CorMedix 1 2 3 Entry into US Market for Hemodialysis 4 Initial Neutrolin Indication: Hemodialysis Possible expanded Indications: Oncology, ICU, Parenteral Nutrition, Peritoneal
Slide 11: Strategy: Successful EU Launch for Hemodialysis
11 © 2013 CorMedix Strategy: Successful EU Launch for Hemodialysis • Successful launch in Germany and Austria – Experienced sales team – Increase healthcare provider awareness – Sales being booked: not yet shipped • Negotiate partner arrangements • Position Neutrolin ® strategically – Pricing – Unde
Slide 12: Strategy: Label Expansion in EU
Slide 13: Strategy: Rollout to Other Key Countries
13 © 2013 CorMedix Strategy: Rollout to Other Key Countries • Identify best sales partners in key countries • Complete agreements • Monitor product positioning and coordinate manufacturing capacity
Slide 14: Strategy: Entry Into US Market
14 Strategy: Entry Into US Market U.S. FDA discussions (pre-IND meeting, timelines) FDA clinical trial requirements Duration Clinical trial execution decision Strategic partner © 2013 CorMedix • – • • •
Slide 15: Neutrolin Growth Strategy
15 © 2013 CorMedix Neutrolin Growth Strategy Phase I: Europe for Hemodialysis and label expansions Phase II: Other key countries for Hemodialysis Phase III: Hemodialysis in the U.S.
Slide 16: Defined Market and Upside Potential by Region
16 $130M © 2013 CorMedix $130M $80M $15M $15M $30M $30M $20M $15M $100M $130M Hemodialysis - Defined Market Label Expansions - Defined Market (oncology, ICU, total parenteral nutrition and peritoneal dialysis) Hemodialysis - Upside Potential Label Expansions - Upside Potential (oncology, ICU, total
Slide 17: IP Status Update
17 © 2013 CorMedix IP Status Update • Global Patent Portfolio - 17 issued patents provide protection through 2019- 2025 – Freedom to Operate in Europe – Proprietary • Planned additional filings
Slide 18: Financial Information
18 © 2013 CorMedix Financial Information • Total Pro Forma cash of approximately $3.3 million as of September 30, 2013 • Total Pro Forma debt of approximately $0.3 million as of September 30, 2013 • Capitalized to fund operations through the second quarter of 2014 assuming no sales and/or strategic
Slide 19: Investment Highlights
© 2013 CorMedix Investment Highlights CorMedix ( NYSE MKT: CRMD ) develops and markets products to treat renal, cardiac and infectious diseases Lead product Neutrolin ® Class III CE Mark approved (drug-device) in July 2013 Catheter-related bloodstream infections (CRBSI) cost approx. $25,000-40,000/h
Slide 20: Thank You
Thank You November 2013 © 2013 CorMedix 745 Route 202-206 Suite 303 Bridgewater, NJ 08807 908.517.9500 (ph) 908.429.4307 (fax) NYSE MKT: CRMD @CorMedix rmilby@cormedix.com